Massachusetts has had Romneycare since 2006. And, while it's different in some ways from Obamacare, it offers insight into what's ahead for US health care.
Saurabh Mukherjea, Head of Equities at Ambit Capital talks to Cash Flow about where to invest in India's pharmaceutical market.
An antibiotic-resistant strain of gonorrhea has some saying that its effects could match those of AIDS.
Rolf-Dieter Schwalb, CFO of DSM, tells CNBC that whilst the nutrition business is doing well, pharma needs improvement.
If you’re selling drug stocks for this reason, Cramer thinks you don’t get the pharma business.
The FDA has lowered the age limit for Plan B One-Step emergency contraceptive to 15. The pill will be available without a prescription and stocked on store shelves.
One biotech name has the best upside potential for 2013, pharmaceutical analyst Barbara Ryan says.
Pfizer will report earnings on Tuesday before the market open. The FMHR traders debate the bull and the bear case for the stock. Barbara Ryan, FTI Strategic Communications, shares her recommendations for investing in pharma stocks now.
Novartis plied physicians with dinners, speaker fees, fishing trips and outings at Hooters restaurants to get them to prescribe patients more Novartis drugs, the US government alleges. Globalpost reports.
Germany's Bayer has agreed to buy U.S. contraceptive devices maker Conceptus for $1.1 billion, aiming to underpin its position as the world's largest women's healthcare provider.
A proposed merger of Valeant Pharmaceuticals International Inc and Actavis Inc. was put on hold after the two drugmakers failed to agree on terms of a deal.
Get ready. Cramer sees the potential for problems around Wednesday.
Michael Sinclair, CEO of Advanced Oncotherapy, explains why his company acquired Swiss firm Adam SA this week, citing its leadership in technology advancements.
Pockets of weakness in the market have captured Cramer's attention. Is the selling really warranted?
Novartis was sued on Tuesday by the United States, which accused the Swiss drug maker of using kickbacks to induce pharmacies to steer thousands of patients to its drug.
Amgen's stock fell sharply in after-hours trading after it reported sales that fell short of Wall Street's expectations.
Big pharma is abandoning antibiotic research at a time when fears over superbugs are growing at an alarming rate, leaving smaller firms to fill the breach.
It will take a mix of approaches to make health care more affordable, Johnson & Johnson CEO Alex Gorsky told CNBC.
Antibiotic-resistant bacteria—often called "superbugs"—are entering the nation's food system and endangering consumers at an alarming rate, according to an analysis of government data.
A British professor says that drug abuse helped bring about the financial crisis, but he may have pinned the blame on the wrong drug.